La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Prelude Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Prelude Therapeutics..

Prelude Therapeutics (NASDAQ:PRLD) Azioni, Catena delle Opzioni

PRELUDE THERAPEUTICS INC

Prelude Therapeutics

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

<a href="https://x.com/SecDef/status/1943401411431026977" title="https://x.com/SecDef/status/1943401411431026977">https://x.com/SecDef/status/1943401411431026977</a>

News

AVAV

RCAT

UAVS

Secretary of Defense Pete Hegseth Signs Memo, Announces Efforts To Boost Drone Industry

Leerink Partners analyst Faisal Khurshid maintains Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Outperform and raises the price target from $88 to $102.

Price Target

Analyst Ratings

RYTM

Leerink Partners Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $102

Seattle-based EASE Protocol has launched a no-code solution called AutoTasks, allowing non-technical users to deploy smart contracts in under a minute. 
The tool, available via the EASE SuperApp, is designed to simplify blockchain interaction by eliminating the need for coding skills, blockchain-specific knowledge or testing environments.
AutoTasks enables users to configure secure, pre-audited smart contracts using a Setup Wizard that requires only basic input, such as selecting use cases and providing relevant parameters. 
Supported features at launch include payment splitting, digital certificate issuance, IP-protected art releases, account sharing, governance tools, loyalty point systems, and storefront creation.
According to Douglas Horn, architect of the EASE Protocol, AutoTasks addresses a common usability problem in blockchain adoption: the difficulty of deploying smart contracts without introducing technical risks or relying on external developers. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46345201/bitcoins-rally-to-112000-yes-its-different-this-time">Bitcoin&#8217;s Rally To $112,000: Yes, It&#8217;s Different This Time</a>
"Users can hit a button and have a task handled for them automatically," Horn said.
AutoTasks does not use generative AI to write custom contracts, instead relying on pre-compiled, audited templates to reduce execution risk. 
This contrasts with some newer platforms that generate custom code via AI models, a method often flagged for reliability concerns.
The EASE team said the product is built on an ISO-compliant architecture and aims to offer a user experience more akin to mainstream web applications than traditional Web3 platforms. 
The company sees this launch as a step toward bringing decentralized technology to a wider, less technical audience, including enterprises and government users.
Read Next: • <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46340086/bitrue-backs-politically-linked-stablecoin-usd1-despite-expected-pushback-over-trump-ties">Bitrue Backs Politically-Linked Stablecoin USD1 Despite Expected Pushback Over Trump Ties</a>
Photo: Harsamadu via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Can One Button Really Launch A Smart Contract? EASE's New Toolkit Says Yes

Although the innovation ecosystem has started to look interesting again as evidenced by the recent performance of the Nasdaq Composite index, Akamai Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>) has been a conspicuous laggard. Since the start of the year, the content delivery network (CDN) specialist — which also offers robust cybersecurity and edge computing services — has dropped nearly 17%. Nevertheless, AKAM stock could be an intriguing candidate for a sentiment reversal.
Fundamentally, Akamai plays a vital role in how people and enterprises consume the internet — it's just that the essential work occurs behind the scenes. Using a geographically distributed network of proxy servers, CDNs help speed up websites by storing cached content near end-users. This capability is especially critical for companies with content-streaming arms, such as Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>, NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>).
Further, Akamai plays an important (albeit indirect) role in artificial intelligence. Today, many AI models — especially those involving voice assistants, fraud detection services and personalized ads — require <a href="https://www.benzinga.com/sec/24/09/40814222/from-latency-to-a-i-algo-driven-capital-markets">low latency</a> or minimal lag in data transmission between source and destination. Thanks to Akamai's edge computing infrastructure, AI workloads can run closer to the user, reducing delay and bandwidth strain.
Finally, Akamai offers a strong cybersecurity suite, including advanced protocols such as zero-trust security. Given the importance of digital protection, it's arguably one of the key line items that companies <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/03/44501515/cybersecurity-stocks-to-outperform-its-the-one-line-item-that-no-company-in-the-world-is-cutting-josh-brown">can't afford to skimp out on</a>.
Unfortunately, recent financial performances reflect <a href="https://www.benzinga.com/quote/AKAM">revenue pressures</a>, which points to a highly competitive environment. Further, while Akamai is making progress in cybersecurity, that arena is also crowded. Essentially, the company needs to prove that its edge computing services can scale profitably; hence, the volatility in AKAM stock.
<h2 class="wp-block-heading">Applying Game Theory To Formulate A Strategy In AKAM Stock</h2>
At the heart of every market-related discussion is a game of probabilities. People are looking to see whether their investment idea of choice will likely move higher or not; otherwise, why bother having the discussion in the first place? But merely listing out the pros and cons of a security won't empirically get us any closer to the answer.
To better understand AKAM stock as a trading prospect, it's helpful to consider this thought experiment. Imagine flipping a fair coin 100 times every business day. What you flip on Monday will have no bearing on what you flip on Tuesday and so forth. That's simply because coin tosses are random events.
Now imagine that the stock market is also random. If so, we could look at various intervals in the past and the long-side success ratio for each session in the interval would be about the same: 50%. That's not what we see at all.
By converting the price action of AKAM stock into market breadth — or sequences of accumulative and distributive sessions — we can filter out the messy noise of price discovery and get down to root demand sentiments. Further, segregating market breadth into 10-week sequences (using data from January 2019 onward) reveals the following profile:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Ticker</td>
<td>L10 Category</td>
<td>Sample Size</td>
<td>Up Probability</td>
<td>Baseline Probability</td>
<td>Delta</td>
<td>Median Return if Up</td>
</tr>
<tr>
<td>AKAM</td>
<td>2-8-D</td>
<td>1</td>
<td>100.00%</td>
<td>58.82%</td>
<td>41.18%</td>
<td>0.33%</td>
</tr>
<tr>
<td>AKAM</td>
<td>3-7-D</td>
<td>11</td>
<td>72.73%</td>
<td>58.82%</td>
<td>13.91%</td>
<td>1.47%</td>
</tr>
<tr>
<td>AKAM</td>
<td>3-7-U</td>
<td>1</td>
<td>100.00%</td>
<td>58.82%</td>
<td>41.18%</td>
<td>0.37%</td>
</tr>
<tr>
<td>AKAM</td>
<td>4-6-D</td>
<td>34</td>
<td>61.76%</td>
<td>58.82%</td>
<td>2.94%</td>
<td>2.65%</td>
</tr>
<tr>
<td>AKAM</td>
<td>4-6-U</td>
<td>4</td>
<td>50.00%</td>
<td>58.82%</td>
<td>-8.82%</td>
<td>3.37%</td>
</tr>
<tr>
<td>AKAM</td>
<td>5-5-D</td>
<td>47</td>
<td>53.19%</td>
<td>58.82%</td>
<td>-5.63%</td>
<td>1.94%</td>
</tr>
<tr>
<td>AKAM</td>
<td>5-5-U</td>
<td>22</td>
<td>72.73%</td>
<td>58.82%</td>
<td>13.91%</td>
<td>1.69%</td>
</tr>
<tr>
<td>AKAM</td>
<td>6-4-D</td>
<td>37</td>
<td>56.76%</td>
<td>58.82%</td>
<td>-2.06%</td>
<td>2.03%</td>
</tr>
<tr>
<td>AKAM</td>
<td>6-4-U</td>
<td>53</td>
<td>54.72%</td>
<td>58.82%</td>
<td>-4.10%</td>
<td>1.80%</td>
</tr>
<tr>
<td>AKAM</td>
<td>7-3-D</td>
<td>12</td>
<td>50.00%</td>
<td>58.82%</td>
<td>-8.82%</td>
<td>3.35%</td>
</tr>
<tr>
<td>AKAM</td>
<td>7-3-U</td>
<td>52</td>
<td>53.85%</td>
<td>58.82%</td>
<td>-4.97%</td>
<td>1.82%</td>
</tr>
<tr>
<td>AKAM</td>
<td>8-2-D</td>
<td>3</td>
<td>100.00%</td>
<td>58.82%</td>
<td>41.18%</td>
<td>7.32%</td>
</tr>
<tr>
<td>AKAM</td>
<td>8-2-U</td>
<td>38</td>
<td>68.42%</td>
<td>58.82%</td>
<td>9.60%</td>
<td>1.91%</td>
</tr>
<tr>
<td>AKAM</td>
<td>9-1-U</td>
<td>5</td>
<td>20.00%</td>
<td>58.82%</td>
<td>-38.82%</td>
<td>2.14%</td>
</tr>
</tbody>
</table>
</figure>
In the trailing two months, AKAM stock is printing a "4-6-D" sequence: four up weeks, six down weeks, with a negative trajectory across the 10-week period. This is a relatively uncommon sequence, having materialized 34 times. However, the biggest takeaway is that in 61.76% of cases, the following week's price action results in upside, with a median return of 2.65%.
Based on the current market price, the statistical response to the 4-6-D sequence suggests that AKAM stock could hit $81.87, perhaps push toward $82 given its psychological lull.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10151246/AKAM-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-980673" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10151246/AKAM-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10151246/AKAM-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10151246/AKAM-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/10151246/AKAM-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
Broadly, what makes the above framework appealing is the non-randomness of the market. If AKAM stock traded randomly, then all the sequences should roughly coalesce around the 50% probability mark. They don't. Instead, some sequences are clearly favorable for the bullish speculator.
Rather than trying to trade AKAM stock based on curated opinions, I believe it's better to use game theory; that is, make a move when the odds favor you.
<h2 class="wp-block-heading">Two Trades To Consider</h2>
Based on the market intelligence above, the nearest-term strategy to consider is the 79/81 bull call spread expiring July 18. This transaction involves buying the $79 call and simultaneously selling the $81 call, for a net debit paid of $110 (the most that can be lost in the trade). Should AKAM stock rise through the short strike price ($81) at expiration, the maximum reward is $90, a nearly 82% payout.
If you want to ramp up the reward, you could opt for the 80/82 bull spread also expiring next Friday. While this trade features a maximum payout of roughly 111%, it also requires AKAM stock to move that much further by expiration.
The other trade to consider is the 75/85 bull call spread expiring Aug. 15. This trade provides five weeks for AKAM stock to rise to the required profitability threshold, with the breakeven price presently at $80.25. Here, the net debit required is $525 with a maximum payout of 90.48%.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/07/46332032/cop-stock-conocophillips-contrarian-lifeline">Options Corner: Why ConocoPhillips May Have Received A Contrarian Lifeline</a></li>
</ul>
Photo: Shutterstock

Equities

Long Ideas

Options

AAPL

AKAM

GOOG

GOOGL

NFLX

Options Corner: Why Low-Key Infrastructure Play Akamai Technologies Might Surprise You

Tech giant Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) is expected to join the growing list of smartphone companies <a href="https://www.benzinga.com/markets/tech/25/07/46319996/qualcomms-most-powerful-chip-yet-is-here-and-its-built-to-unlock-samsungs-galaxy-ai">with foldable smartphones </a>with a new iPhone Fold expected to launch next year.
What Happened: Apple has been working on a reported <a href="https://www.benzinga.com/tech/25/04/44850406/apples-foldable-iphone-rumors-gain-steam-as-stock-slides-could-a-2000-device-spark-a-comeback">foldable iPhone for years</a>, but waited until it got specifications and production right before a full launch.
That launch is nearing and expected in 2026, with a production line almost ready, according to a report from <a href="https://9to5mac.com/2025/07/10/iphone-fold-production-line-almost-ready-for-next-years-launch-report/" target="_blank" rel="noopener">9to5Mac</a>.
The latest report indicates that the production line will be capable of producing twice as many foldable iPhones as the company actually expects to sell.
Unlike others in the tech world, Apple doesn't operate with a first-to-market mentality; instead, it lives by a "best, not first" mantra. The company has waited to make sure it got everything right with the foldable smartphone.
Among the key items Apple has examined ahead of production are dust and the visible crease that appears when the screen is unfolded. Apple told suppliers to try again after it was not pleased with the initial samples.
Read Also: <a href="https://www.benzinga.com/news/earnings/25/05/45152493/apple-reports-strong-q2-earnings-revenue-beat-eps-beat-installed-base-hits-all-time-high-across-all-segments-100-billion-buyback-and-more">Apple Reports &#8216;Strong&#8217; Q2 Earnings: Revenue Beat, EPS Beat, Installed Base Hits All-Time High Across All Segments, $100 Billion Buyback And More</a>
Why It's Important: The latest report comes months after a report that Apple was testing prototypes of the foldable iPhone ahead of its highly anticipated launch.
Samsung, which has its own foldable smartphones, is a partner for Apple on the phone's display. The report said the iPhone Fold display could be more advanced than what Samsung is using for its own foldable phones.
The iPhone Fold is expected to cost around $2,000 for consumers, which could limit initial demand for Apple's new foldable smartphone.
Apple is hedging its bets on the phone becoming more popular than initially projected and plans to have production capabilities for partners like Samsung to manufacture double the number of screens it initially required.
The report said Apple plans to sell six million to eight million foldable iPhones in the first year of availability.
AAPL Price Action: Apple stock trades at $212.81 on Thursday versus a 52-week trading range of $169.21 to $260.09. Apple stock is down 13% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/03/44366890/apple-stock-faces-pressure-from-declining-iphone-revenue-could-companys-first-foldable-smartphone-in-2026-reverse-course">Apple Stock Faces Pressure From Declining iPhone Revenue: Could Company&#8217;s First Foldable Smartphone In 2026 Reverse Course?</a></li>
</ul>
Photo: Mr.Mikla / Shutterstock.com

Tech

Trading Ideas

Apple's Foldable iPhone Could Land In 2026, And Leave Samsung Playing Catch-Up

Between July 2, 2025 and July 8, 2025, Hyperscale Data, Inc. (the "Company") issued an aggregate of 1,117,133 shares of Class A Common Stock upon conversion of approximately 1,130.34 shares of Series B Convertible Preferred Stock. Between July 2, 2025 and July 8, 2025, the Company issued an aggregate of 183 shares of Class A Common Stock upon conversion of an equal number of shares of Class B Common Stock. The shares of Class A Common Stock were issued in reliance upon exemption from the registration requirements under Section 4(a)(2) under the Securities Act of 1933, as amended.
&nbsp;
On July 9, 2025, the Company issued 427,565 shares of Class A Common Stock upon conversion of $440,381 of an outstanding convertible note. The Class A Common Stock were offered and sold in reliance upon an exemption from the registration requirements under Section 3(a)(9) under the Securities Act.
&nbsp;
As of July 9, 2025, the Company had 16,689,864 shares of Class A Common Stock outstanding.

Offerings

GPUS

Hyperscale Data Issues 1,117,133 Class A Shares From Series B Preferred Conversion, 183 Shares From Class B Conversion Between July 2-8, 2025 And 427,565 Shares From $440K Note Conversion On July 9, 2025

WIIM

CIVB

Civista Bancshares shares are trading lower after the company announced it will acquire The Farmers Savings Bank and launched a public offering.

TKNO

Alpha Teknova Files For Up To $225,000,000 Mixed Shelf

KALV

KalVista Pharmaceuticals Entered Into Sales Agreement, Offering Up to $100M Common Stock

Liberty Broadband Corporation ("Liberty Broadband") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>, LBRDK, LBRDP))), announced today that, in connection with its upcoming spin-off (the "Spin-Off") of its wholly owned subsidiary GCI Liberty, Inc. ("GCI Liberty"), it has been advised by Nasdaq that shares of GCI Liberty's Series A common stock and Series C common stock will trade on a when-issued basis on The Nasdaq Global Select Market under the symbols "GLBAV" and "GLBKV", respectively, from July 11, 2025 through July 14, 2025. The Spin-Off is expected to occur after market-close on July 14, 2025 through the distribution, by means of a dividend, of GCI Liberty common stock to holders of record of Liberty Broadband common stock as of 5:00 p.m., New York City time, on June 30, 2025, the record date for the distribution. However, because Nasdaq has established July 15, 2025 as the ex-dividend date for the distribution, and as a result of related "due bill" trading procedures, persons acquiring shares of Liberty Broadband's Series A common stock and Series C common stock in the market through July 14, 2025 will still receive the respective shares of GCI Liberty in the Spin-Off. GCI Liberty Series A common stock and Series C common stock will begin trading in the regular way on Tuesday, July 15, 2025 on The Nasdaq Stock Market under the symbols "GLIBA" and "GLIBK", respectively. GCI Liberty Series B common stock has been approved for quotation on the OTC Markets under the symbol "GLIBB," and quoting is expected to begin on or around Monday, July 21, 2025.

Dividends

LBRDA

LBRDK

LBRDP

Liberty Broadband Spin-Off Of GCI Liberty Set For July 14, 2025; When-Issued Trading Begins July 11, 2025 Under "GLBAV" & "GLBKV", Regular Trading Starts July 15, 2025 On Nasdaq

Janney Montgomery Scott analyst Daniel Cardenas initiates coverage on Burke &amp; Herbert Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHRB#NASDAQ">BHRB</a>) with a Buy rating and announces Price Target of $70.

Initiation

BHRB

Janney Montgomery Scott Initiates Coverage On Burke & Herbert Financial with Buy Rating, Announces Price Target of $70

General

RKLB

Rocket Lab Selects Bollinger Shipyards To Support The Build Out Of Rocket Lab's Ocean Landing Platform For Its Neutron Reusable Rocket

Ryder Increases Quarterly Cash Dividend From $0.81 To $0.91

Management

Toll Brothers Appoints Gregg Ziegler To Succeed Marty Connor As CFO

Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) has outperformed the market over the past 5 years by 2.21% on an annualized basis producing an average annual return of 16.64%. Currently, Travelers Companies has a market capitalization of $58.00 billion. 
Buying $1000 In TRV: If an investor had bought $1000 of TRV stock 5 years ago, it would be worth $2,240.81 today based on a price of $255.99 for TRV at the time of writing.
<h3>Travelers Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752179434_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Travelers Companies 5 Years Ago Would Be Worth Today

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 25.26% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed up 21.34% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 14.58% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 12.50% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 12.03% at $0.35</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 8.82% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 8.31% at $0.07</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 6.80% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 3.84% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 3.34% at $0.34</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 3.20% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 3.05% at $0.10</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed down 33.50% at $1.35</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 14.29% at $0.0006</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 14.29% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 14.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 12.20% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RSSFF">Affinor Growers</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RSSFF#OTC">RSSFF</a>) shares closed down 6.65% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed down 5.43% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 5.05% at $0.64</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 4.93% at $3.06</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Growth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed down 4.79% at $1.19</li>
<li><a href="https://www.benzinga.com/quote/BLGVF">Belgravia Hartford Cap</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLGVF#OTC">BLGVF</a>) shares closed down 3.10% at $0.25</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BBRRF

BLGVF

CBDY

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CNBX

CNTMF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CWBHF

FFNTF

GBHPF

GNLN

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

MRMD

NWVCF

OILFF

RSSFF

SOLCF

TGIFF

TLRY

UGRO

Cannabis Stock Movers For July 10, 2025

Guidance

LEVI

During Conference Call, Levi Strauss CFO Reportedly Says Co Has Brought 60% Of Inventory Needed To Get Through Second Half Of The Year

Canaccord Genuity analyst Brian McNamara maintains EZCORP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZPW#NASDAQ">EZPW</a>) with a Buy and raises the price target from $24 to $25.

EZPW

Canaccord Genuity Maintains Buy on EZCORP, Raises Price Target to $25

NVVE

Nuvve Holding shares are trading lower after the company announced a proposed public offering.

Nuvve Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) (the "Company" or "Nuvve"), a global leader in vehicle-to-grid (V2G) technology and grid modernization, today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Lucid Capital Markets is acting as the sole book-running manager for the offering.

Nuvve Holding Corp. Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed

Health Care

Press Releases

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

Earnings

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

Prelude Announces Presentations at 2025 AACR Annual Meeting

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Comments

Prelude Therapeutics

Prelude Therapeutics (PRLD) Opzioni

Prelude Therapeutics (NASDAQ:PRLD) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO